Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc. | AVTX-002 (quisovalimab) - (PEAK) | Non-Eosinophilic Asthma (NEA) | Phase 2 | Ongoing | Intravenous | Respiratory |
| Avalo Therapeutics Inc. | AVTX-803 - (LADDER) | Leukocyte Adhesion Deficiency Type II (LAD II) | Phase 3 | Ongoing | Oral | Genetic Disorder |
| Avalo Therapeutics Inc. | AVTX-802 | Mannose phosphate isomerase deficiency related CDG (MPI-CDG) | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Avalo Therapeutics Inc. | CERC-301 | Major depressive disorder (MDD) | Phase 2 | Trial Discontinued | Oral | Psychiatric |
| Avalo Therapeutics Inc. | AVTX-009 (anti-IL-1β mAb) - (LOTUS) | Hidradenitis suppurativa (HS) | Phase 2 | Ongoing | Intravenous | Immunology: Anti-TNF |
| Avalo Therapeutics Inc. | CERC-501 | Smoking cessation | Phase 2 | Trial Discontinued | oral | Anti-Addiction |
| Avalo Therapeutics Inc. | AVTX-002 | COVID-19 induced Acute Respiratory Distress Syndrome (ARDS) | Phase 2 | Data Released | Intravenous | Respiratory |
| Avidity Biosciences Inc. | del-desiran (AOC 1001) - (HARBOR) | Myotonic dystrophy type 1 (DM1) | Phase 3 | Hold Removed | Intravenous | Genetic Disorder |
